Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1 trial of K0706, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): In patients with chronic myelogenous leukemia (CML) and phildelphia positive acute lymphoblastic leukemia (Ph + ALL) failing ≥ 3 prior TKI therapies: Initial safety and efficacy
    Meeting Abstract

    Cortes, J. E.; Kim, D. W.; Nicolini, F. E.; Saikia, T.; Charbonnier, A.; Apperley, J. F.; Rathnam, K.; Deininger, M. W.; De Lavallade, H.; Khattry, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Cytogenetic and molecular response with first- and second-generation tyrosine kinase inhibitor (TKI) therapy in simplicity: An observational study of patients with chronic-phase chronic myeloid Leukemia (CP-CML)
    Meeting Abstract

    Cortes, J. E.; Chen, C.; Davis, C.; Goldberg, S. L.; Mauro, M. J.
    Blood (2019)

    Fulltext@MSK | Save
  • Plasmacytoid dendritic cell proportion is predictive of risk and outcomes in myelodysplastic syndromes
    Meeting Abstract

    Chan, A.; Zhang, Y.; Devlin, S. M.; Lewis, N.; Baik, J.; Arcila, M. E.; Klimek, V. M.; Roshal, M.; Xiao, W.
    Blood (2019)

    Fulltext@MSK | Save
  • Newly diagnosed AML patient samples demonstrate high degree of concordance in identification of pathogenic mutations by next generation sequencing (NGS) performed at enrolling institutions compared to central laboratory results in the Beat AML Master Trial
    Meeting Abstract

    Borate, U.; Ruppert, A. S.; Yang, F.; Jones, D.; Caruthers, S.; Zhao, W.; Vergilio, J. A.; Burd, A.; Pavlick, D.; Juckett, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Time to second treatment as a proxy for overall survival in CLL/SLL: Identifying risk factors to help guide treatment selection
    Meeting Abstract

    Bantilan, K. S.; Soumerai, J. D.; Roeker, L. E.; Mato, A. R.; Zelenetz, A. D.
    Blood (2019)

    Fulltext@MSK | Save
  • Combined venetoclax and hypomethylating agent (HMA) therapy induces high response rates in patients with myelodysplastic syndrome including patients previously failing HMA
    Meeting Abstract

    Ball, B. J.; Famulare, C.; Stein, E. M.; Tallman, M. S.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; Testi, R.; Al Ali, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ongoing results of a phase 1B/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies
    Meeting Abstract

    Allan, J. N.; Patel, K.; Mato, A. R.; Wierda, W. G.; Pinilla Ibarz, J.; Choi, M. Y.; O'Brien, S. M.; Sharman, J. P.; Shadman, M.; Gladstone, D. E.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Intestinal microbiome analyses identify biomarkers for patient response to CAR T cell therapy
    Meeting Abstract

    Smith, M.; Littmann, E.; Slingerland, J.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Peled, J. U.; Park, J.; O'Cearbhaill, R.; Mailankody, S.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Impact of pre-transplant measurable residual disease on relapse incidence and progression-free survival in older AML/MDS patients following allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Lin, R. J.; Elko, T. A.; Devlin, S. M.; Perales, M. A.; Papadopoulos, E. B.; Castro-Malaspina, H.; Gyurkocza, B.; Shaffer, B. C.; Tamari, R.; Tallman, M.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save